ISIS News Alert Isis Pharmaceuticals (ISIS) 65.44 01/06/2015

New Post Public Reply Private Reply Replies (0) Message Board

Jan 6, 2015 at 6:53 PM

Isis Pharmaceuticals (ISIS) 65.44 $ISIS

AOL and Gilead Sciences are big market movers
AP - 23 mins ago
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
F: 14.62 (-0.14), K.TO: 3.95 (+0.47), CS: 23.81 (-0.43), BBEP: 6.90 (+0.08), SDRL: 10.48 (-0.33), NBG: 1.58 (-0.08), CYBX: 54.36 (-3.43), JNJ: 103.28 (-0.51), ISIS: 65.44 (-2.73), KGC: 3.33 (+0.38), AOL: 46.25 (+1.51), CVEO: 3.11 (-0.32), EBIX: 18.60 (+2.32), THLD: 3.55 (-0.13), CEMP: 23.15 (-1.40), VZ: 47.04 (+0.47), XOOM: 16.82 (-0.07)

Isis Pharmaceuticals Up on Collaboration with J&J - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 33 mins ago
Isis Pharmaceuticals (ISIS) inked a global collaboration with Johnson & Johnson's (JNJ) Janssen Biotech, Inc for the discovery and development of antisense drugs for treating autoimmune disorders of the gastrointestinal tract.
BIIB: 334.65 (-2.09), JNJ: 103.28 (-0.51), ISIS: 65.44 (-2.73), AZN: 68.16 (-1.70)

Public Shame for Biotechs Not Webcasting 'JPM15' Breakout Sessions
at The Street - Tue Jan 06, 2:08PM CST
In a blow to investor transparency, an embarrassingly small number of healthcare companies are webcasting their Q&A breakout sessions at next week's J.P. Morgan Healthcare Conference.
BLUE: 95.24 (+3.19), BIIB: 334.65 (-2.09), VRTX: 117.36 (-3.67), ISIS: 65.44 (-2.73), SGEN: 31.45 (-1.60), GILD: 97.65 (+0.86), AMGN: 152.90 (-5.09), AGIO: 111.43 (+2.56), BMY: 58.48 (-0.10), CELG: 110.51 (-1.42)

Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015
at The Street - Tue Jan 06, 10:52AM CST
TheStreet's Adam Feuerstein lays down his predictions for the biotech industry for 2015.
BLUE: 95.24 (+3.19), BIIB: 334.65 (-2.09), QCOR: 93.60 (+1.52), ISIS: 65.44 (-2.73), GILD: 97.65 (+0.86), PFE: 31.42 (+0.26), VVUS: 2.94 (-0.10), JUNO: 51.66 (+5.71), BMY: 58.48 (-0.10), MNKD: 5.57 (-0.13), ARNA: 3.32 (-0.20), PBYI: 188.12 (-0.25), CELG: 110.51 (-1.42)

Company News for January 06, 2015 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 9:10AM CST
Companies in the News are: KITE,AMGN,STI,ISIS,NPSP,GS
JNJ: 103.28 (-0.51), GS: 184.53 (-3.81), ISIS: 65.44 (-2.73), KITE: 71.45 (+1.70), NPSP: 41.05 (+2.92), STI: 39.08 (-1.16), AMGN: 152.90 (-5.09)

Critical Alerts For JetBlue, Isis Pharmaceuticals, Gold Fields, 58.com and 51job Released By InvestorsObserver
PR Newswire - Tue Jan 06, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for JBLU, ISIS, GFI, WUBA and JOBS.
WUBA: 40.57 (-1.97), JOBS: 36.62 (-0.49), ISIS: 65.44 (-2.73), GFI: 5.24 (+0.25), JBLU: 14.97 (-0.25)

Isis Pharmaceuticals (ISIS) in Focus: Stock Soars 10.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 8:21AM CST
Isis Pharmaceuticals, Inc. (ISIS) was a big mover last session, as the company saw its shares rise around 11% on the day.
ISIS: 65.44 (-2.73), AFFX: 9.94 (-0.05)

Scaling New Heights: Complimentary Research on Stereotaxis, Kite Pharma, ISIS Pharma, Merck and General Motors
PR Newswire - Tue Jan 06, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Stereotaxis (NASDAQ: STXS), Kite Pharma (NASDAQ: KITE), ISIS Pharma (NASDAQ: ISIS), Merck (NYSE: MRK), and General Motors (NYSE: GM). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ISIS: 65.44 (-2.73), KITE: 71.45 (+1.70), MRK: 60.32 (+2.28), GM: 34.85 (+0.52), STXS: 1.70 (-0.18)

New business head at Isis
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 6:01AM CST

ISIS: 65.44 (-2.73)

Isis Pharmaceuticals Appoints Paula Soteropoulos As President And Chief Executive Officer Of Akcea Therapeutics
PR Newswire - Tue Jan 06, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the appointment of Paula Soteropoulos as president and chief executive officer (CEO) of Akcea Therapeutics, the Isis-owned, lipid franchise subsidiary responsible for the development and commercialization of Isis' lipid drugs, ISIS-APOCIIIRx, ISIS-APO(a)Rx, ISIS-ANGPTL3Rx,and their more potent LICA follow-ons.
ISIS: 65.44 (-2.73)

Jim Cramer's Top Stock Picks: INTC UNH HD MSFT CSCO ISIS
at The Street - Tue Jan 06, 5:00AM CST
Cramer is bullish about a lot of stocks going into 2015 including Microsoft, Cisco and Isis Pharmaceuticals.
HD: 100.95 (-0.31), ISIS: 65.44 (-2.73), UNH: 98.92 (-0.20), MSFT: 45.65 (-0.68), INTC: 35.28 (-0.67), CSCO: 27.05 (-0.01)

Isis Pharmaceuticals to discover and develop RNA-targeted therapeutics for autoimmune diseases in the GI Tract in partnership with Janssen
M2 - Tue Jan 06, 4:02AM CST
Drug company Isis Pharmaceuticals (NasdaqGS:ISIS) reported on Monday the launch of a global collaboration to discover and develop antisense drugs to treat autoimmune disorders of the gastrointestinal (GI) tract in three programmes in collaboration with Janssen Biotech.
ISIS: 65.44 (-2.73)

Isis Pharmaceuticals hires Sarah Boyce as its chief business officer
M2 - Tue Jan 06, 3:53AM CST
Novel drugs company Isis Pharmaceuticals (NasdaqGS:ISIS) disclosed on Monday the election of Sarah Boyce as its chief business officer as well as as a member of its executive leadership team.
ISIS: 65.44 (-2.73)

Jim Cramer's 'Mad Money' Recap: My 10 Ways to Make Your 2014 Gains Continue in 2015
at The Street - Mon Jan 05, 7:27PM CST
Tried and true conventional wisdom seemed to be best strategy last year, Cramer says.
SWIR: 44.77 (-2.21), CY: 13.69 (-0.53), HD: 100.95 (-0.31), PRU: 85.44 (-1.81), UNH: 98.92 (-0.20), INTC: 35.28 (-0.67), SLB: 81.72 (-1.63), SBUX: 79.23 (-0.65), ISIS: 65.44 (-2.73), S: 4.19 (-0.02), CVS: 94.23 (+0.07), MSFT: 45.65 (-0.68), AAPL: 106.26 (+0.01), SLCA: 24.26 (-0.59), CSCO: 27.05 (-0.01), TRV: 103.24 (-0.93)

Isis Pharmaceuticals Appoints Sarah Boyce As Chief Business Officer
PR Newswire - Mon Jan 05, 5:00PM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that Sarah Boyce has joined the company as chief business officer. In this newly created position, Ms. Boyce will provide strategic leadership from a commercial background and lead Isis' corporate development activities, including corporate communications, business development, patient advocacy, competitive intelligence and alliance management. Ms. Boyce will also serve as a member of Isis' executive leadership team.
ISIS: 65.44 (-2.73)

Isis inks development deal with J&J
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 12:48PM CST

JNJ: 103.28 (-0.51), ISIS: 65.44 (-2.73)

Isis Pharma To Develop GI Drugs With J&J
at Investor's Business Daily - Mon Jan 05, 12:17PM CST
Biotech Isis Pharmaceuticals (ISIS) leapt 10% to a new high above 68 In the stock market today after it signed a licensing deal with Johnson & Johnson worth up to $835 million. J&J's (JNJ) Janssen Biotech arm agreed to pay $35 million upfront and up...
BIIB: 334.65 (-2.09), JNJ: 103.28 (-0.51), ISIS: 65.44 (-2.73), GSK: 41.68 (-0.23)

Jim Cramer: Isis Pharmaceuticals Gets a 'Gigantic' Boost With J&J Deal
at The Street - Mon Jan 05, 10:53AM CST
Cramer says Isis shares are going even higher thanks to a $835 million licensing deal with J&J and a subsidiary.
JNJ: 103.28 (-0.51), ISIS: 65.44 (-2.73), REGN: 396.89 (-15.58)

Today's Market: Biotech Names Rallying, Retail Buyout Candidates
Matthew Smith - at Seeking Alpha - Mon Jan 05, 9:08AM CST

JNJ: 103.28 (-0.51), BBBY: 75.42 (-0.43), ISIS: 65.44 (-2.73), PIR: 14.77 (-0.37), DKS: 49.24 (-0.43), DIA: 173.39 (-1.45), CEMP: 23.15 (-1.40), MAR: 74.67 (-0.95), PCLN: 1,079.96 (-17.62)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 8:10AM CST

CERS: 5.78 (-0.79), E: 32.08 (+0.12), SSL: 34.64 (-0.36), CNAT: 10.63 (+0.57), SDRL: 10.48 (-0.33), NBG: 1.58 (-0.08), BCLI: 5.00 (-0.75), URZ: 1.20 (+0.02), PBR: 6.02 (-0.05), ISIS: 65.44 (-2.73), KITE: 71.45 (+1.70), PLX: 2.02 (-0.15), CEMP: 23.15 (-1.40), STXS: 1.70 (-0.18)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stoke Space Raises $1B; XTEND AI Hits NYSE

A Billion-Dollar Boost for Stoke Space Ever catch wind of a company hauling in a cool billion and shrug it off? Me neither. Stoke Space Technologies just locked down $1 billion in Series E funding. This ain't some pocket change—the kind of dough you need when you're eyeing stars and plotting orbital voyages. They're gearing up for a 2027 mission with their Nova...

ASCEND® Cladding Unveils New Profiles & Texture Variety

New Options for Creative Home Exteriors Amid today's housing market rollercoaster, a sprinkle of bold innovation in building materials can make a statement—and that's precisely what Associated Materials Innovations (AMI) is banking on with their latest beef-up in the ASCEND® Composite Cladding lineup. Introduced out of Cuyahoga Falls on Sept. 8, 2026, this expansion...

VitalCore Pioneers Jail Behavioral Health Expansion

The Big Move in Correctional Healthcare VitalCore Health Strategies has made an impressive move with the opening of a 60-bed Behavioral Health Unit at Shawnee County Jail in Topeka, Kansas. The unit, part of a $21 million expansion completed on August 24, is set to change the landscape for inmates needing mental health and substance use treatment. This isn't just a slap...

Big Wins at Americas Cardroom's $15M Venom Series

High Stakes and Huge Paydays: The Venom Breakdown Alright, folks, here's a tale of how the cards fell in one of the most electrifying poker standoffs at Americas Cardroom. With prize pools clocking in at a staggering $15.095 million, the Dual Mystery Bounty Venoms really stacked the chips high. From the gritty, bustling halls of the internet to the proverbial green-felt...

Spot the Signs: Early Gum Disease Insights from Experts

Why Early Detection of Gum Disease Matters Let's dive right into the crux of things. Gum disease, that sneaky antagonist of oral health, starts unassumingly. You brush, you floss, but those gums might still bleed—ever noticed? Dr. Marian Burgard of Fairport Family Dental has a thing or two to say about this, enlightening us through an insightful piece by HelloNation....

Everpure Surges into the S&P 500: A Milestone Move

Big Leagues Beckon: Everpure Enters the S&P 500 Another day, another dollar, but today ain't just any day for Everpure. They’re stepping up from the minor leagues and grabbing their spot in the illustrious S&P 500 lineup. We're talking about a milestone that every company dreams of, but few achieve—this ain't your regular Tuesday headline. Stock Market's Stamp of...

Innventure Faces Major Lawsuit Amidst Market Turmoil

The Plot Thickens with Innventure's DarkNX Project Buckle up, fellow market sling-riders; the Innventure tale is a rocky one for the books. Imagine this: You’ve plunked down your hard-earned cash on Innventure Inc. (NASDAQ: INV), lured by their glowing pronouncements about a supposed golden egg project, the Accelsius DarkNX data-center deal. A big talk about...

AllyGPO Shines as Top Innovator in Health Tech

Innovative Excellence in Healthcare Tech It's not every day you see a specialty group purchasing organization like AllyGPO snagging a spot on Fast Company's esteemed list of Best Workplaces for Innovators. Making it into the top half at number 40 in 2026, it’s a testament to a company really leaning into employee-driven innovation. And, buddy, this ain't just corporate...

Drunk Angel Celebrates First Year in Crystal Jewelry

One Year Down, A Unique Path Forward It's been a year since Drunk Angel jumped into the online jewelry scene, and they're setting themselves apart in their own glittery lane. Imagine starting a brand that's not just about pretty trinkets, but about linking those tiny treasures to timeless traditions. They've got their sights set on blending the deep tales of gemstones...

MADD, Uber Rally at Capital Invitational for Safe Choices

Driving Change at the Capital Invitational Let's talk about a powerhouse collaboration aiming to do more than just thrill basketball fans. We're looking at MADD Sports, Uber, and the Capital Invitational joining forces at The St. James in Springfield, Virginia, on December 10, 2026. This is not your average sporting event; it's a gathering with a bigger purpose. The...